Adrenergic agonist

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Cardiology Network

Discuss Adrenergic agonist further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

WikiDoc Resources for

Adrenergic agonist

Articles

Most recent articles on Adrenergic agonist

Most cited articles on Adrenergic agonist

Review articles on Adrenergic agonist

Articles on Adrenergic agonist in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Adrenergic agonist

Images of Adrenergic agonist

Photos of Adrenergic agonist

Podcasts & MP3s on Adrenergic agonist

Videos on Adrenergic agonist

Evidence Based Medicine

Cochrane Collaboration on Adrenergic agonist

Bandolier on Adrenergic agonist

TRIP on Adrenergic agonist

Clinical Trials

Ongoing Trials on Adrenergic agonist at Clinical Trials.gov

Trial results on Adrenergic agonist

Clinical Trials on Adrenergic agonist at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Adrenergic agonist

NICE Guidance on Adrenergic agonist

NHS PRODIGY Guidance

FDA on Adrenergic agonist

CDC on Adrenergic agonist

Books

Books on Adrenergic agonist

News

Adrenergic agonist in the news

Be alerted to news on Adrenergic agonist

News trends on Adrenergic agonist

Commentary

Blogs on Adrenergic agonist

Definitions

Definitions of Adrenergic agonist

Patient Resources / Community

Patient resources on Adrenergic agonist

Discussion groups on Adrenergic agonist

Patient Handouts on Adrenergic agonist

Directions to Hospitals Treating Adrenergic agonist

Risk calculators and risk factors for Adrenergic agonist

Healthcare Provider Resources

Symptoms of Adrenergic agonist

Causes & Risk Factors for Adrenergic agonist

Diagnostic studies for Adrenergic agonist

Treatment of Adrenergic agonist

Continuing Medical Education (CME)

CME Programs on Adrenergic agonist

International

Adrenergic agonist en Espanol

Adrenergic agonist en Francais

Business

Adrenergic agonist in the Marketplace

Patents on Adrenergic agonist

Experimental / Informatics

List of terms related to Adrenergic agonist

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

An adrenergic is a drug, or other substance, which has effects similar to, or the same as, epinephrine (adrenaline). Thus, they are a kind of sympathomimetic agents. Alternatively, it may refer to something which is susceptible to epinephrine, or similar substances, such as a biological receptor (specifically, the adrenergic receptors).

Beta blockers block the action of epinephrine and norepinephrine in the body. Adrenergic drugs either stimulate a response (agonists) or inhibit a response (antagonists). The five categories of adrenergic receptors are: α1, α2, β1, β2, and β3, and agonists vary in specificity between these receptors, and may be classified respectively. However, there are also other mechanisms of adrenergic agonism. Epinephrine and norepinephrine are endogenous and broad-spectrum. More selective agonists are more useful in pharmacology.

α1 agonists

α1 agonists: stimulates phospholipase C activity. (vasoconstriction and mydriasis; used as vasopressors, nasal decongestants & eye exams). Selected examples are:

α2 agonists

α2 agonists: inhibits adenylyl cyclase activity. (reduce brainstem vasomotor center-mediated SNS activation; used as antihypertensives, sedatives & treatment of opiate & alcohol withdrawal symptoms). Selected examples are:

  • Clonidine (mixed alpha2-adrenergic and imidazoline-I1 receptor agonist)
  • Guanfacine (preference for alpha2A-subtype of adrenoceptor)
  • Guanabenz (most selective agonist for alpha2-adrenergic as opposed to imidazoline-I1)
  • Guanoxabenz (metabolite of guanabenz)
  • Guanethidine (periferal alpha2-receptor agonist)

β1 agonists

β1 agonists: stimulates adenylyl cyclase activity; opening of calcium channel. (cardiac stimulants; used to treat cardiogenic shock, acute heart failure, bradyarrhythmias). Selected examples are:

β2 agonists

β2 agonists: stimulates adenylyl cyclase activity; closing of calcium channel (smooth muscle relaxants; used to treat asthma and COPD). Selected examples are:

Other mechanisms

See also

External links




WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch

Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .